Jove
Visualize
Contact Us

Related Experiment Videos

Sibrafiban (Genentech).

C A Feldstein1

  • 1Institute of Health Sciences School of Medicine, Universidad Privada, Av Las Heras 2191, Buenos Aires, Argentina.

Idrugs : the Investigational Drugs Journal
|September 13, 2005
PubMed
Summary
This summary is machine-generated.

Sibrafiban is an oral antithrombotic drug targeting GPIIb/IIIa receptors. It is currently in phase III clinical trials, with potential marketing approval and launch anticipated in the near future.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary care role in awareness and control of hypertension: a hospital-based study.

International journal of clinical practice·2008
Same author

Salt intake, hypertension and diabetes mellitus.

Journal of human hypertension·2002
Same author

Insulin resistance and hypertension in postmenopausal women.

Journal of human hypertension·2002
Same author

Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values.

Journal of human hypertension·2001
Same author

Relationship between hyperinsulinemia and ambulatory blood pressure monitoring of lean and overweight male hypertensives.

Journal of cardiovascular risk·1998
Same author

[Arterial hypertension as a risk factor in the cardiovascular complications of diabetes mellitus].

Revista clinica espanola·1992
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Sibrafiban (G-7453) is an orally active non-peptide glycoprotein IIb/IIIa antagonist.
  • It is under development by Genentech and Hoffmann-La Roche.

Purpose of the Study:

  • To evaluate Sibrafiban as a novel antithrombotic agent.
  • To assess its efficacy and safety in ongoing phase III clinical trials.

Main Methods:

  • The study involves phase III clinical trials.
  • Investigational approach focuses on antithrombotic activity.

Main Results:

  • Sibrafiban is in phase III trials, indicating promising preclinical and early clinical data.
  • The drug demonstrates potential as an antithrombotic therapy.

Conclusions:

  • Sibrafiban shows potential as an orally active antithrombotic agent.
  • The drug is progressing through late-stage clinical development.